Patent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer'sBusiness Wire • 12/19/23
IGC Pharma Announces Participation in Biotech Showcase and BioPartnering @ JPM Alongside the J.P. Morgan 41st Annual Healthcare Conference 2024Business Wire • 12/13/23
IGC Pharma Announces Master Agreement with Leading South American University to Advance AI InitiativesBusiness Wire • 11/21/23
IGC Pharma Granted European Patent for Groundbreaking Cannabinoid-Based Pain Topical Relief TherapyBusiness Wire • 10/19/23
IGC Pharma Reports First Quarter Results; Company Continues to Make Significant Progress Advancing Its Lead Alzheimer's Candidate Through Phase 2 Clinical TrialsBusiness Wire • 08/14/23
IGC Pharma Expands Phase 2 Trial of IGC-AD1 to Include the University of Puerto RicoBusiness Wire • 08/02/23
IGC Pharma, Inc. Presenting 6 Posters on the Positive Impact of IGC-AD1 on Neuropsychiatric Symptoms in Dementia at the 2023 Alzheimer's Association International ConferenceBusiness Wire • 07/18/23
IGC Pharma Secures $12 Million Line of Credit from O-Bank Strengthening Efforts in Alzheimer's ResearchBusiness Wire • 07/07/23
IGC Pharma, Inc. to Present at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023 & Hold 1x1 Meetings on Thursday, April 27, 2023Accesswire • 04/18/23
IGC Applauds Signing of Bipartisan Medical Marijuana and Cannabidiol Research Expansion ActGlobeNewsWire • 12/07/22
IGC Commences Phase 2 Clinical Trials Evaluating Drug Candidate IGC-AD1 for the Treatment of Agitation in Dementia From Alzheimer's DiseaseBusiness Wire • 12/01/22